Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ribozymes02:47

Ribozymes

13.8K
The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can...
13.8K
Ribozymes02:47

Ribozymes

3.9K
3.9K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

37
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
37
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.8K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.4K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.4K
RNA Interference01:23

RNA Interference

28.9K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[From viral disease gender to viral species subclassification: how to find our way around?]

Virologie (Montrouge, France)·2024
Same author

MicroRNAs and long non-coding RNAs during transcriptional regulation and latency of HIV and HTLV.

Retrovirology·2024
Same author

Gene therapy to cure HIV infection.

Virologie (Montrouge, France)·2023
Same author

[Gene therapy to cure HIV infection].

Virologie (Montrouge, France)·2023
Same author

[A year in Virologie: some viruses persist, others emerge].

Virologie (Montrouge, France)·2022
Same author

The discovery and development of RNA-based therapies for treatment of HIV-1 infection.

Expert opinion on drug discovery·2022

Related Experiment Video

Updated: Apr 16, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.3K

HIV and Ribozymes.

Robert J Scarborough1, Anne Gatignol

  • 1Department of Microbiology and Immunology, McGill University, 3999 Cote Ste Catherine Street, Montreal, QC, Canada, H3T 1E2.

Advances in Experimental Medicine and Biology
|March 12, 2015
PubMed
Summary
This summary is machine-generated.

Modified ribozymes show promise as therapeutics for HIV-1 infection. Studies highlight optimal strategies for RNA gene therapy, positioning these catalytic RNA molecules as competitive candidates for future treatments.

More Related Videos

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.7K

Related Experiment Videos

Last Updated: Apr 16, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.3K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.7K

Area of Science:

  • Biochemistry and Molecular Biology
  • RNA Catalysis
  • Antiviral Therapeutics

Background:

  • Ribozymes are catalytic RNA molecules with diverse biological functions, including gene regulation and protein synthesis.
  • Naturally occurring ribozymes have been engineered for therapeutic applications, particularly for HIV-1 infection.
  • RNA gene therapy represents a novel approach to treating viral diseases.

Purpose of the Study:

  • To summarize preclinical and clinical data on ribozymes as potential HIV-1 therapies.
  • To describe modified ribozyme motifs, target sites, and expression strategies.
  • To review RNA conjugations and clinical trial outcomes for anti-HIV-1 ribozymes.

Main Methods:

  • Review of preclinical and clinical studies on anti-HIV-1 ribozymes.
  • Analysis of modified ribozyme designs, including target sites and expression methods.
  • Evaluation of RNA conjugation techniques to enhance antiviral efficacy.
  • Summary of results from conducted clinical trials.

Main Results:

  • Various ribozyme motifs have been successfully modified for anti-HIV-1 activity.
  • Different expression strategies and RNA conjugations have been explored to optimize therapeutic effects.
  • Clinical trials have provided valuable insights into the efficacy and safety of ribozyme-based therapies.
  • Studies have identified optimal protocols for RNA gene therapy in the context of HIV-1.

Conclusions:

  • Anti-HIV-1 ribozyme research has significantly advanced the understanding of RNA gene therapy.
  • Optimized ribozyme designs and delivery methods show continued potential for HIV-1 treatment.
  • Ribozymes remain competitive candidates for future therapeutic strategies against HIV-1 infection.